Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002087 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals
A Phase 1 study, sponsored by Pharmacia and Upjohn.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002087: Completed Phase 1 study, sponsored by Pharmacia and Upjohn.
NCT00002087 is a Phase 1 study that has completed, run by Pharmacia and Upjohn. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002087, a Phase 1 study, has completed, sponsored by Pharmacia and Upjohn.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To investigate the safety and tolerance of an increasing number of infusions per week of alvircept sudotox ( sCD4-PE40; soluble CD4-Pseudomonas exotoxin ) at a fixed dose when administered to HIV-1-infected individuals. To investigate the effect of sCD4-PE40 on the following parameters: T lymphocyte subsets, plasma HIV RNA and cellular HIV proviral DNA in PBMC and CD4 cells, p24 levels, serum beta-2 microglobulin, and neopterin levels.
Interventions
- DRUG Alvircept sudotox
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
What the finished NCT00002087 record still lists
NCT00002087 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Alvircept sudotox is the first listed.
NCT00002087 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002087 about?
NCT00002087 is a clinical study titled "Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals". To investigate the safety and tolerance of an increasing number of infusions per week of alvircept sudotox ( sCD4-PE40; soluble CD4-Pseudomonas exotoxin ) at a fixed dose when administered to HIV-1-infected individuals. To investigate the effect of sCD4-PE40 on the following parameters: T lymphocyte...
What is the current status of trial NCT00002087?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00002087?
The interventions under investigation include: Alvircept sudotox (DRUG).
Who is sponsoring clinical trial NCT00002087?
This trial is sponsored by Pharmacia and Upjohn, which has 11 total clinical trials registered on ClinicalTrials.gov.